Explore the words cloud of the TIPPDECRA project. It provides you a very rough idea of what is the project "TIPPDECRA" about.
The following table provides information about the project.
UNIVERSITY OF NEWCASTLE UPON TYNE
|Coordinator Country||United Kingdom [UK]|
|Total cost||183˙454 €|
|EC max contribution||183˙454 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2016-05-05 to 2018-05-04|
Take a look of project's partnership.
|1||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||coordinator||183˙454.00|
After obtaining my PhD at the University of Utrecht in the Netherlands, I moved to San Diego for a 1-year postdoc at the La Jolla Institute for Allergy and Immunology. I now propose to move to Newcastle University in the United Kingdom to undertake a project on a new cell-based therapy for rheumatoid arthritis (RA), a destructive joint disease. This project is important since this new therapy could provide long-term benefit to RA patients. So far I have conducted all my work in mouse models. This project will enable me to acquire new expertise in human immunology and translational research. The host team at Newcastle University has developed a new immunotherapy for RA with tolerogenic dendritic cells (tolDC). These tolDC have been designed to switch-off destructive immune responses in the joint via the induction of regulatory T cells. The team has completed a phase I trial with tolDC in RA, and has found that the therapy is safe. However, in order to conduct a phase II efficacy trial, one crucial aspect of tolDC therapy must be improved: loading of tolDC with a relevant (auto)antigen so that they can induce antigen-specific regulatory T cells in the joint. However, selecting a suitable auto-antigen has been problematic. I propose that heat shock proteins (HSPs) are suitable antigens for loading of tolDC. HSPs are ubiquitously expressed in the rheumatoid synovium and pathogenic T-cell responses to these HSPs are found in RA patients. I hypothesise that by loading tolDC with exogenous synthetic peptides from HSPs, the pathogenic response can be suppressed through the induction of HSP-specific regulatory T cells. My project aims to i) establish a suitable HSP-peptide selection for tolDC-induced peptide-specific tolerance in RA patients and ii) test the therapeutic potential of HSP-peptide-loaded tolDC in a mouse arthritis model. A successful outcome of this work would form the basis of a new clinical trial with HSP-loaded tolDC in RA patients.
|year||authors and title||journal||last update|
Manon A. A. Jansen, Rachel Spiering, Femke Broere, Jacob M. van Laar, John D. Isaacs, Willem van Eden, Catharien M. U. Hilkens
Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?
published pages: 51-59, ISSN: 0019-2805, DOI: 10.1111/imm.12811
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIPPDECRA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TIPPDECRA" are provided by the European Opendata Portal: CORDIS opendata.